These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35306318)

  • 21. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
    Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
    Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
    Antonarelli G; Corti C; Zucali PA; Perrino M; Manglaviti S; Lo Russo G; Varano GM; Salvini P; Curigliano G; Catania C; Conforti F; De Pas T
    Eur J Cancer; 2022 Oct; 174():31-36. PubMed ID: 35970033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chappell KJ; Mordant FL; Amarilla AA; Modhiran N; Liang B; Li Z; Wijesundara DK; Lackenby JA; Griffin P; Bennet JK; Hensen L; Zhang W; Nguyen THO; Tran MH; Tapley P; Barnes J; Reading PC; Kedzierska K; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
    EBioMedicine; 2023 Nov; 97():104842. PubMed ID: 37865043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study.
    Pietroluongo E; Peddio A; De Placido P; Tortora M; Ottaviano M; Gelzo M; Cernera G; Foggia M; Buonomo AR; Pinchera B; Zappulo E; Mercinelli S; Cattaneo L; Sardanelli A; Viceconte G; Scotto R; Schiano Moriello N; Servetto A; De Angelis C; Arpino G; Palmieri G; De Placido S; Bianco R; Castaldo G; Gentile I; Giuliano M
    BMC Cancer; 2024 Jun; 24(1):748. PubMed ID: 38898390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
    Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
    mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serologic Status According Severe Acute Respiratory Syndrome Coronavirus 2 in Patients After Orthotopic Heart Transplantation.
    Kuczaj A; Przybyłowski P
    Transplant Proc; 2022 May; 54(4):901-904. PubMed ID: 35414422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases: insights from the COVAD study.
    Alunno A; Carubbi F; Tan AL; Sen P; Cavagna L; Joshi M; Day J; Saha S; Gutiérrez CET; Caballero-Uribe CV; Distler O; Chinoy H; Aggarwal R; Agarwal V; Gupta L;
    Rheumatol Int; 2024 Sep; 44(9):1725-1731. PubMed ID: 39003346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
    Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
    Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
    Baden LR; El Sahly HM; Essink B; Kotloff K; Frey S; Novak R; Diemert D; Spector SA; Rouphael N; Creech CB; McGettigan J; Khetan S; Segall N; Solis J; Brosz A; Fierro C; Schwartz H; Neuzil K; Corey L; Gilbert P; Janes H; Follmann D; Marovich M; Mascola J; Polakowski L; Ledgerwood J; Graham BS; Bennett H; Pajon R; Knightly C; Leav B; Deng W; Zhou H; Han S; Ivarsson M; Miller J; Zaks T;
    N Engl J Med; 2021 Feb; 384(5):403-416. PubMed ID: 33378609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
    Anderson EJ; Rouphael NG; Widge AT; Jackson LA; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Corbett KS; Swanson PA; Padilla M; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Martinez DR; Baric R; Buchanan W; Luke CJ; Phadke VK; Rostad CA; Ledgerwood JE; Graham BS; Beigel JH;
    N Engl J Med; 2020 Dec; 383(25):2427-2438. PubMed ID: 32991794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.
    Tyner HL; Burgess JL; Grant L; Gaglani M; Kuntz JL; Naleway AL; Thornburg NJ; Caban-Martinez AJ; Yoon SK; Herring MK; Beitel SC; Blanton L; Nikolich-Zugich J; Thiese MS; Pleasants JF; Fowlkes AL; Lutrick K; Dunnigan K; Yoo YM; Rose S; Groom H; Meece J; Wesley MG; Schaefer-Solle N; Louzado-Feliciano P; Edwards LJ; Olsho LEW; Thompson MG
    Clin Infect Dis; 2022 Aug; 75(1):e827-e837. PubMed ID: 34928334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.